Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells

BACKGROUND: Combined endocrine therapy with a cyclin-dependent kinase (CDK) 4/6 inhibitor has been indicated to improve not only progression-free survival, but also overall survival in patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancer. However, resistance to this com...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Breast Cancer
Main Authors: Ogata, Ryohei, Kishino, Emi, Saitoh, Wataru, Koike, Yoshikazu, Kurebayashi, Junichi
Format: Artigo
Sprog:Inglês
Udgivet: Springer Japan 2020
Fag:
Original Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7796879/
https://ncbi.nlm.nih.gov/pubmed/32860163
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12282-020-01150-8
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker